Streetbeat News

Revenues

PGEN

Precigen, Inc. is set to present its commercial plans for PRGN-2012, a potential FDA-approved treatment for RRP, at the J.P. Morgan Healthcare Conference. The company has completed its BLA submission and is preparing for a potential launch in the second half of 2025. With a cash runway extending into 2026, Precigen is well-positioned financially. The market opportunity for PRGN-2012 in the US is estimated at 27,000 adult patients, with further potential in other HPV-driven indications.

Portfolio Pulse from

January 13, 2025 | 12:15 pm

MAKOF

Mako Mining Corp. reported record gold revenue of $28.8 million for Q4 2024 from its San Albino gold mine in Nicaragua, along with a cash increase of $9.5 million. The company also provided an update on its Eagle Mountain Gold Project in Guyana.

Portfolio Pulse from

January 13, 2025 | 12:15 pm

EDAP

EDAP TMS SA reported preliminary record sales for its Focal One System in Q4 2024, with 11 systems sold globally and a 30% year-over-year increase in U.S. procedures.

Portfolio Pulse from

January 13, 2025 | 12:15 pm

RRGB

Red Robin Gourmet Burgers, Inc. reported positive preliminary revenue results for Q4 2024, indicating growth in comparable restaurant revenue.

Portfolio Pulse from

January 13, 2025 | 12:15 pm

ELDN

Eledon Pharmaceuticals has completed enrollment in its Phase 2 BESTOW trial for tegoprubart in kidney transplantation ahead of schedule, with results expected in late 2025. The company also reported positive data from ongoing trials and secured $135 million in financing to support operations through 2026.

Portfolio Pulse from

January 13, 2025 | 12:15 pm

PRPL

Purple Innovation, Inc. (NASDAQ: PRPL) revised its full-year 2024 guidance, expecting net revenue between $486 and $488 million and adjusted EBITDA between $(23) and $(21) million. The company anticipates positive cash flow and adjusted EBITDA in Q4 2024. Purple will participate in the 2025 ICR Conference.

Portfolio Pulse from

January 13, 2025 | 12:15 pm

GILT

Gilat has received over $3 million in orders to support Low Earth Orbit (LEO) constellations, reinforcing its position as a key provider of high-performance RF solutions for Non-Geostationary Satellite Orbit (NGSO) networks.

Portfolio Pulse from

January 13, 2025 | 12:15 pm

SOTK

Sono-Tek Corporation reported its third consecutive quarter with revenues exceeding $5 million and a 3% year-over-year growth for the first nine months of fiscal 2025. The company maintains a strong backlog of $10.6 million and projects over $20 million in revenue with continued profitability for the fiscal year.

Portfolio Pulse from

January 13, 2025 | 12:15 pm

MRNA

Moderna announced updates at the J.P. Morgan Healthcare Conference, reporting 2024 product sales of $3.0 to 3.1 billion and a cash balance of $9.5 billion. The company expects 2025 revenue of $1.5 to 2.5 billion and plans to reduce cash costs by $1.0 billion in 2025 and an additional $0.5 billion in 2026. Moderna anticipates milestones in 10 programs, including potential approvals and data readouts.

Portfolio Pulse from

January 13, 2025 | 12:15 pm

LAB

Standard BioTools has announced its preliminary, unaudited revenue for the full year 2024, totaling approximately $174 million. The company will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 16th, 2024.

Portfolio Pulse from

January 13, 2025 | 12:15 pm